MedX Health lebt noch - Testpilot mit EmpowerClinics zu Telederamtologie - 500 Beiträge pro Seite
eröffnet am 10.03.21 09:45:57 von
neuester Beitrag 17.08.21 10:03:48 von
neuester Beitrag 17.08.21 10:03:48 von
Beiträge: 24
ID: 1.344.311
ID: 1.344.311
Aufrufe heute: 0
Gesamt: 606
Gesamt: 606
Aktive User: 0
ISIN: CA5850901037 · WKN: A0YJHF · Symbol: MDX
0,1000
CAD
+11,11 %
+0,0100 CAD
Letzter Kurs 26.04.24 TSX Venture
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,9700 | +324,79 | |
| 0,5800 | +26,94 | |
| 0,6570 | +26,59 | |
| 0,5700 | +23,38 | |
| 4,4000 | +19,08 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,3700 | -11,61 | |
| 0,5480 | -12,74 | |
| 0,5600 | -14,85 | |
| 0,6835 | -20,53 | |
| 1,8819 | -55,93 |
Feedback
heute wurde bekannt gegeben, dass MedX Health ein Pilotproject zur Teledermatologie mit Empower Clinics starten wird.
NEWS dazu
https://ceo.ca/@accesswire/empower-clinics-and-medx-health-t…
NEWS dazu
https://ceo.ca/@accesswire/empower-clinics-and-medx-health-t…
Ergänzend zur News gab es gestern ein Interview auf agoracom indem Mike Druhan (Präsident MedX) und Steven McAuley (CEO Empower Clinics) nochmals genauer auf den Piloten und die Zusammenarbeit der beiden Unternehmen eingegangen sind.
Hier für alle Interessierten auch noch ein paar mehr Infos um sich selbst ein Bild zu machen.
Interview mit Mike Druhan:
News zur Markterschließung:
Brasilien: https://ceo.ca/@businesswire/medx-health-signs-exclusive-dis…-dermsecure-in-brazil-where-skin-cancer-is-prevalent" target="_blank" rel="nofollow ugc noopener">https://ceo.ca/@businesswire/medx-health-signs-exclusive-dis…-dermsecure-in-brazil-where-skin-cancer-is-prevalent
Mexico: https://ceo.ca/@businesswire/medx-health-signs-exclusive-dis…
Niederlande: https://ceo.ca/@businesswire/medx-health-corp-announces-the-…
Nordamerika: https://ceo.ca/@businesswire/medx-health-corp-expands-north-…
Interview mit Mike Druhan:
News zur Markterschließung:
Brasilien: https://ceo.ca/@businesswire/medx-health-signs-exclusive-dis…-dermsecure-in-brazil-where-skin-cancer-is-prevalent" target="_blank" rel="nofollow ugc noopener">https://ceo.ca/@businesswire/medx-health-signs-exclusive-dis…-dermsecure-in-brazil-where-skin-cancer-is-prevalent
Mexico: https://ceo.ca/@businesswire/medx-health-signs-exclusive-dis…
Niederlande: https://ceo.ca/@businesswire/medx-health-corp-announces-the-…
Nordamerika: https://ceo.ca/@businesswire/medx-health-corp-expands-north-…
Interview bei proaktive mit Mike Druhan über die Company selbst und den Piloten mit Empower Clinics und zwei Daycare Kliniken in Ontario:
Ein kurzes Update zum Testballon mit Empower Clinics bzgl Teledermatologie:
Gestern hat der CEO von Empower Clinics in einer Q&A Session gesagt, dass die ersten 3 Klinik wohl im Juni 2021 eröffnet werden. Ich nehme an, dass dann auch der POC beginnen wird.
Gestern hat der CEO von Empower Clinics in einer Q&A Session gesagt, dass die ersten 3 Klinik wohl im Juni 2021 eröffnet werden. Ich nehme an, dass dann auch der POC beginnen wird.
Trading Spotlight
NEWS - Info über Präsentation von MedX beim Planet MicroCap Virtual Event 22.4.2021
https://ceo.ca/@businesswire/medx-health-to-present-at-the-p…
https://ceo.ca/@businesswire/medx-health-to-present-at-the-p…
NEWS - neuer CRO
https://ceo.ca/@businesswire/medx-health-corp-names-health-c…
MedX Health Corp. Names Health-Care Leader Sylvain Desjeans as Chief Revenue Officer
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce the appointment of Sylvain Desjeans as Chief Revenue Officer. With more than 30 years of health-care industry experience, Mr. Desjeans is a seasoned leader who has successfully implemented and led large-scale strategic growth plans and global product licensing initiatives for international pharmaceutical and medical companies. He comes to MedX from tenures as Country Manager (Canada) for Aspen Pharmacare and senior leadership positions at Accucaps Industries Limited and Biovail Pharmaceuticals.
Mr. Desjeans will lead market access, customer acquisition, engagement and marketing for MedX’s teledermatology offering as the Company accelerates its international expansion efforts and continues the growth of its network of approved clinical partners across Canada, including Empower Clinics. Mr. Desjeans will also work closely with the chair of MedX’s Medical Advisory Board, Dr. Trevor Champagne, on the Company’s artificial intelligence technology, driving ongoing innovation and patient-driven product development.
"Sylvain brings a wealth of experience to our growing team as we continue to scale our operations to meet international demand and increasing uptake within the North American market,” said Robert von der Porten, Acting CEO and Chairman. "His experience, leadership and relationships will secure further market access as we set our sights on new opportunities given the growing need for teledermatology to support health-care systems, globally. His background in dermatology – and specifically working with dermatologists – will bring value to our partner clinicians and customers.”
Mr. Desjeans stated, "MedX is poised for significant international market expansion with its best-in-class SIAscopy® skin-scanning device and DermSecure® platform. This technology reduces the strain on health-care systems by offering a truly patient-centric experience, which ultimately improves patient outcomes.”
MedX’s leading telemedicine platform allows health-care practitioners to quickly and accurately assess suspicious moles, lesions and other skin conditions via its image capture technology, SIAscopy®, and its secure, cloud-based patient management system, DermSecure®, which transmits and stores patient data throughout the assessment process. MedX’s SIAscopy® is the only technology that captures five images, including four spectrophotometric images 2mm below the skin’s surface.
Teledermatology, a subspecialty of dermatology that offers safe and effective virtual care —patient assessment and diagnosis— at a distance, eliminates the need for in-person appointments. With the world navigating through ongoing COVID-19 recovery measures, teledermatology's advancement has never been more critical to patient care and outcomes.
https://ceo.ca/@businesswire/medx-health-corp-names-health-c…
MedX Health Corp. Names Health-Care Leader Sylvain Desjeans as Chief Revenue Officer
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce the appointment of Sylvain Desjeans as Chief Revenue Officer. With more than 30 years of health-care industry experience, Mr. Desjeans is a seasoned leader who has successfully implemented and led large-scale strategic growth plans and global product licensing initiatives for international pharmaceutical and medical companies. He comes to MedX from tenures as Country Manager (Canada) for Aspen Pharmacare and senior leadership positions at Accucaps Industries Limited and Biovail Pharmaceuticals.
Mr. Desjeans will lead market access, customer acquisition, engagement and marketing for MedX’s teledermatology offering as the Company accelerates its international expansion efforts and continues the growth of its network of approved clinical partners across Canada, including Empower Clinics. Mr. Desjeans will also work closely with the chair of MedX’s Medical Advisory Board, Dr. Trevor Champagne, on the Company’s artificial intelligence technology, driving ongoing innovation and patient-driven product development.
"Sylvain brings a wealth of experience to our growing team as we continue to scale our operations to meet international demand and increasing uptake within the North American market,” said Robert von der Porten, Acting CEO and Chairman. "His experience, leadership and relationships will secure further market access as we set our sights on new opportunities given the growing need for teledermatology to support health-care systems, globally. His background in dermatology – and specifically working with dermatologists – will bring value to our partner clinicians and customers.”
Mr. Desjeans stated, "MedX is poised for significant international market expansion with its best-in-class SIAscopy® skin-scanning device and DermSecure® platform. This technology reduces the strain on health-care systems by offering a truly patient-centric experience, which ultimately improves patient outcomes.”
MedX’s leading telemedicine platform allows health-care practitioners to quickly and accurately assess suspicious moles, lesions and other skin conditions via its image capture technology, SIAscopy®, and its secure, cloud-based patient management system, DermSecure®, which transmits and stores patient data throughout the assessment process. MedX’s SIAscopy® is the only technology that captures five images, including four spectrophotometric images 2mm below the skin’s surface.
Teledermatology, a subspecialty of dermatology that offers safe and effective virtual care —patient assessment and diagnosis— at a distance, eliminates the need for in-person appointments. With the world navigating through ongoing COVID-19 recovery measures, teledermatology's advancement has never been more critical to patient care and outcomes.
NEWS von gestern - Private placement
https://www.businesswire.com/news/home/20210514005511/en/
https://www.businesswire.com/news/home/20210514005511/en/
Hier mal ein sehr interessanter Beitrag zur Entwicklung des Teledermatology Marktes bis 2027
https://www.fortunebusinessinsights.com/teledermatology-mark…
https://www.fortunebusinessinsights.com/teledermatology-mark…
UPDATE zur NEWS vom 28.10.2020 - MedX Health Corp. Expands North American Clinic Sales
Vielleicht haben es einige noch nicht gesehen oder wissen es noch nicht. Es gibt auf Agoracom.com ein Subsite zu allen Thema bzgl Medx Health.https://agoracom.com/ir/MDX
Hier gab es im April21 ein Update seitens Mike Druhan bzgl des Rollouts in Nordamerikanischen Klinken der Ziemer Professional Group.
News dazu war:
https://www.businesswire.com/news/home/20201028006233/en/Med…
Statement von Mike Druhan bzgl eine Updates:
"We have identified and trained eight of our first ten retail Siascopy scanning centres. The onboarding process has been documented and fine-tuned for scalability in the near future. The training was all conducted remotely due to COVID; however, this is the preferred model again for scalability reasons.
Scanning has begun for in house patients of our first 8 clinics and it is being well received. Certainly, COVID has slowed the patient flow as many of the clinics have experienced closures or repeated closures as they are not all deemed essential services. External marketing will commence including Facebook and email marketing once it is deemed safe to look for new out-of-clinic patients.
From a patient impact view, we have had three cases already early on of patients that needed immediate attention after having their scans evaluated by the Dermatologist. This of course is one of our biggest measures of success and we will document these cases every week."
Update zur NEWS vom 15.06.2020 - MedX Health Signs Exclusive Distribution Agreement to Launch SIAscopy on DermSecure™ in Mexico
Auch zur oben genannten News gab es von Mike Druhan ein Update auf agoracom.com.NEWS vom 15.06.2020:
MedX Health Signs Exclusive Distribution Agreement to Launch SIAscopy on DermSecure™ in Mexico
Update vom 15.03.2021:
"...Covid has had an impact on the regulatory speed in Mexico, unfortunately. The delay has been on both sides of the border. We are now confident we will have regulatory clearance in Q2 and have already started the sales training with our partners in Mexico. Once we have the regulatory clearance I expect a strong stocking order as the team has been building demand through some pre-marketing activities."
ggf. INDIREKTE NEWS für die Zukunft von MedX in Canada
Testflight Partner Empower Clinics hat gestern eine News zur Eröffnung weiterer Kliniken in Canada bekannt gegeben. Zu den bereits 2 Feststehenden - für den Pilot der Teledermatologie ausgewählt - sind bereits jetzt weitere 20 Standorte in den abschließenden Mietverhandlungen. Dies zeigt das kommende Potential für den Einsatz der MedX Technologie, auch wenn es noch etwas dauern wird. Vermutlich bis in Q4, bis alle Kliniken offen sind.Hier zur News:
https://ceo.ca/@accesswire/empower-clinics-kai-medical-at-ho…
Guter Artikel
vllt ist er bezahlt oder nicht. in dem Falle egal. Er spiegelt das wieder, was MedX ist. Die Lösung für das Problem einen Termin beim Dermatologen in Nordamerika zu bekommen.
https://investorintel.com/markets/biotech-healthcare/biotech…
vllt ist er bezahlt oder nicht. in dem Falle egal. Er spiegelt das wieder, was MedX ist. Die Lösung für das Problem einen Termin beim Dermatologen in Nordamerika zu bekommen.
https://investorintel.com/markets/biotech-healthcare/biotech…
NEWS vom 02062021 - MedX Announces $500,000 Non-Brokered Private Placement of Convertible Debenture Loan Notes to Redeem Existing Secured Loan
https://www.businesswire.com/news/home/20210602006131/en/ NEWS vom 10062021 - MedX announces closing of 500000 non brokered private placement
https://www.businesswire.com/news/home/20210610005747/en/ Info News - MedX Announces Issuance of Shares as Compensation for Consulting Services
https://www.businesswire.com/news/home/20210615006218/en/ NEWS - MedX Health Corp. and VidaCeuticals Health Products Inc.
https://www.businesswire.com/news/home/20210615006182/en/ offene Warrants und Optionen aus dem Company Share Plan
ich habe mir heute mal das letzte financial Statement vom 31.5. im Detail angeschaut mit Hinblick auf die offenen Optionen.Laut Statement sind ca. 176Mio Shares im Markt verfügbar.
Offene Optionsscheine mit Fälligkeitsdatum:
Optionen aus dem Company Options Plan:
Vllt hilft das dem ein oder anderen die aktuelle Lage besser einzuschätzen.
Hoffentlich kommen bald News zum Start des Pilottest mit Empower Clinics.
StockOptions laut Company Option Plan nochmal, da der letzte Screen broken ist.
MedX scheint wohl auch betroffen zu sein.
https://www.xetra.com/xetra-de/newsroom/rundschreiben/xetra-…
https://www.xetra.com/xetra-de/newsroom/rundschreiben/xetra-…
Hier der Link zur Website vom CoOp Partner VidaCeuticals Health, wo es im MedX SIAScope geht
https://vidaceuticals.com/vidascan/
https://vidaceuticals.com/vidascan/
Delisting in FRA
stand 13.8. wird MedX morgen in Frankfurt delisted aufgrund von fehlendem TradingVolumen und dem hier:https://www.xetra.com/xetra-en/newsroom/circulars/xetra-circ…
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
